Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OReO: Olaparib Retreatment in Ovarian Cancer
NCT03106987Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2017
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of olaparib in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by AstraZeneca. Started Jun 2017; status: completed.
02
Drugs
olaparib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03106987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03106987.